Neko Health stock
Private-market facts for current and former Neko Health employees researching their stock.
Overview
Neko Health operates preventive health screening clinics using proprietary sensors and AI to perform full-body scans for early disease detection.
Neko Health outlook
For employees evaluating Neko Health equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices. The upside scenario at 4x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Neko Health shares
Why shareholders consider selling
Shareholders in Neko Health may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Neko Health does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Neko Health stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Neko Health shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Neko Health shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series B round and its reported $2B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Neko Health shareholders
Exploring equity in Neko Health often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Neko Health most recently raised a Series B round in January 2025. The company was valued at $2B. Total funding raised to date is approximately $260M.
Founders & company background
Neko Health was founded in 2018 by Hjalmar Nilsonne, Daniel Ek and is headquartered in Stockholm, Sweden.
Industry
Similar private companies
Latest Neko Health news
Frequently asked questions
- Is Neko Health still a private company?
- Yes, Neko Health is currently a private company.
- What is Neko Health's latest funding round?
- Neko Health's most recent known round is Series B, raised in January 2025.
- What is Neko Health's valuation?
- Neko Health's latest reported valuation is $2B.
- Who are the investors in Neko Health?
- Investor information is not currently available.
- Can I sell my Neko Health stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Neko Health stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Neko Health data compiled from funding disclosures, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.